JP2009084202A - 褥瘡の治癒及び/または発生予防剤 - Google Patents
褥瘡の治癒及び/または発生予防剤 Download PDFInfo
- Publication number
- JP2009084202A JP2009084202A JP2007255643A JP2007255643A JP2009084202A JP 2009084202 A JP2009084202 A JP 2009084202A JP 2007255643 A JP2007255643 A JP 2007255643A JP 2007255643 A JP2007255643 A JP 2007255643A JP 2009084202 A JP2009084202 A JP 2009084202A
- Authority
- JP
- Japan
- Prior art keywords
- whey protein
- nutrient
- pressure ulcer
- bedsore
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000004210 Pressure Ulcer Diseases 0.000 title claims abstract description 51
- 230000000069 prophylactic effect Effects 0.000 title 1
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 63
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 62
- 235000021119 whey protein Nutrition 0.000 claims abstract description 54
- 235000015097 nutrients Nutrition 0.000 claims abstract description 31
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 7
- 239000011707 mineral Substances 0.000 claims abstract description 7
- 235000013343 vitamin Nutrition 0.000 claims abstract description 7
- 229930003231 vitamin Natural products 0.000 claims abstract description 7
- 239000011782 vitamin Substances 0.000 claims abstract description 7
- 229940088594 vitamin Drugs 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 5
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 5
- 150000002632 lipids Chemical class 0.000 claims abstract description 5
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 33
- 230000002265 prevention Effects 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 230000035876 healing Effects 0.000 claims description 14
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 235000004252 protein component Nutrition 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 9
- 230000008929 regeneration Effects 0.000 abstract description 7
- 238000011069 regeneration method Methods 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 206010033675 panniculitis Diseases 0.000 abstract description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 abstract description 3
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 description 18
- 239000000203 mixture Substances 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 239000005862 Whey Substances 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000000474 nursing effect Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 102000011632 Caseins Human genes 0.000 description 5
- 108010076119 Caseins Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010068370 Glutens Proteins 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000021312 gluten Nutrition 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 229940001941 soy protein Drugs 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010065713 Gastric Fistula Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000008081 Intestinal Fistula Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940039229 general nutrients Drugs 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【解決手段】筋層再生促進効果を有する乳清蛋白質を有効成分とし,糖質,脂質,ビタミン,ミネラルを含有する乳清蛋白質栄養剤を事前及び/または継続摂取することにより,褥瘡の治癒及び/または発生を予防する.
【選択図】 なし
Description
褥瘡治療に関する基準として,「褥瘡の予防・治療ガイドライン」がある.褥瘡の治療としては,保存的治療と外科的治療があるが,このガイドラインは保存的治療を主体としている.褥瘡は,多方面からの治療が必要で,定時の***変換や清拭,体圧分散用具,栄養管理など看護・介護の占める割合は大きい.なかでも,栄養管理は褥瘡予防・治療に不可欠な組織の耐久性を高め,創傷治癒を促進するために重要である.褥瘡は一旦発症すると完治させることは難しく予防が大切とされてきたが,近年総合的なアセスメントにより適切なケアプランを立てれば治癒も可能となってきた.
栄養組成物による褥瘡の予防・治療を目的とした技術としては,特定組成のアミノ酸を含有する褥瘡予防治療用アミノ酸栄養剤が特開平11-130669号公報(特許文献1)に開示されているが,これはアミノ酸の混合物であることから,味が粗悪で継続摂取は困難と考えられる.
特開2004-284972号公報(特許文献3)には,小麦グルテン,小麦グルテン加水分解物を含有する経腸創傷治療剤が開示されている.これは,小麦グルテン,小麦グルテン加水分解物及び/又は当該加水分解物に相当するポリペプチドを含有する経腸創傷治療剤であるが,その効果は,皮膚表皮の創面積(創面の長径×短径)の減少にとどまっている.圧負荷による循環障害は,皮内の細静脈,筋肉内静脈,筋肉内動脈,皮内細動脈の順に起こることから,表皮,真皮よりも皮下筋層の方が傷害されやすく,表皮のみの創面積の減少では治癒効果とは言い難い.また,褥瘡が浅層にとどまるものは創縁及び創面内からの基底細胞の遊走,進展という過程で治癒するが,深層に及ぶものは肉芽組織の増殖が必要である(臨床看護,31:1456,2005、非特許文献2).
そのため,事前及び/または継続摂取すると褥瘡になりにくく,また褥瘡が発生しても患部皮下組織の筋層再生を促進し,褥瘡を早期治癒させることのできる栄養剤が望まれていた.
(1)乳清蛋白質を有効成分として含有する褥瘡の治癒及び/または発生予防剤.
(2)乳清蛋白質として一日あたり1.25〜2.0g/kg(体重)を経消化管的に投与されるものである上記(1)に記載の褥瘡の治癒及び/または発生予防剤。
(3)上記(1)に記載の褥瘡の治癒及び/または発生予防剤を蛋白質成分として配合した乳清蛋白質配合栄養剤。
(4)糖質,脂質,ビタミン,およびミネラルを配合した上記(2)に記載の乳清蛋白質栄養剤.
(5)前記ビタミンが,少なくともビタミンA及びビタミンCを含有する上記(4)に記載の乳清蛋白質栄養剤.
(6)ミネラルが,少なくともカルシウム,鉄,亜鉛,及び銅を含有する上記(4)または(5)に記載の乳清蛋白質栄養剤.
(7)乳清蛋白質の含有量が,100kcalあたり2〜13.5gである上記(3)〜(6)のいずれかに記載の乳清蛋白質栄養剤。
(8)液状である上記(3)〜(7)のいずれかに記載の乳清蛋白質栄養剤。
(9)高圧蒸気滅菌されてなる上記(8)に記載の乳清蛋白質栄養剤。
本発明の褥瘡の治癒及び/または発生予防剤は、消化管に吸収されるような投与形態であれば、常用されるいずれの投与形態でも,褥瘡の予防・治療効果がある.具体的には、剤形としては液状,固形状,ゲル状,または粉末であってもよく、投与方法としては,経口投与、あるいは経鼻,胃ろう,腸ろうによる経管投与が可能である.
本発明の乳清蛋白質栄養剤中の乳清蛋白質含有量は,2〜13.5g/100kcalが好ましい.2g/100kcal以下では,褥瘡の予防・治療効果が十分に発揮できないほかにも、一般的な栄養剤の蛋白質含有量としては少なく,高齢者や低栄養状態の患者への投与に適していない.また,13.5g/100kcal以上では,蛋白質含有量が過剰となり、配合量に対する効果が相対的に小さくなるばかりでなく、他の栄養成分の摂取も考慮した場合、好ましい栄養バランスから外れがちになる.
本発明の乳清蛋白質栄養剤の投与量は,1日当たり750〜2000kcalが好ましい.乳清蛋白質の投与量としては,1日当たり37.5〜100gが好ましい.
(比較例1) 実施例1において乳清蛋白質の代わりにカゼインナトリウムを配合した以外は実施例1と同様の方法で栄養組成物を調製した.この栄養組成物中に含有されるカゼインは100kcal当たり5.36gである.
(試験例1) 実施例1及び比較例1で調整した栄養組成物を用いて動物実験を行った.ラットを二群に群分けし,一群には実施例1,もう一群には比較例1の栄養組成物を2週間自由摂取させた.これらのラットを用いて,Skalakらの方法(Wound Rep Reg 8:68-76,2000)により褥瘡モデルを作製した.さらに1週間,栄養組成物の摂取を継続し,褥瘡形成部の皮膚を採取した.
(評価例2) 病理標本の強拡大の一視野における再生筋細胞について,画像解析ソフト(Scion Image)を用いて数と面積を計測した.具体的には,多核でH.E.染色で濃染する細胞を再生筋細胞とみなし,選択した.Threshold機能により閾値を設定し2値化処理を行い,細胞数と面積を計測した.一視野全体の面積を計測し,{(再生筋細胞の面積)/(視野全体の面積)}×100(%)の式により面積割合を算出した.その結果,比較例1では細胞数20,面積割合4.50%であったのに対して,実施例1では細胞数32,面積割合6.73%であり,実施例1による皮下筋層の再生促進効果が明らかになった.
Skalakらの褥瘡モデルは,組織学的に皮下筋層に壊死の認められる,臨床の病態をよく反映したモデルである.圧負荷により循環障害を起こし壊死した筋細胞はマクロファージの侵入が起こり,その後,筋衛星細胞の活性化,分化増殖,融合の過程を経て成熟した筋線維となる.乳清蛋白質は,これらの過程のうち筋衛星細胞の活性化,分化増殖促進効果があると考えられる.
(比較例2) 実施例2において乳清蛋白質の代わりに卵白蛋白質を配合した以外は実施例2と同様の方法で卵白蛋白質栄養剤を調製した.得られた卵白蛋白質栄養剤は,チューブに詰まり継続投与不可能であった.また,風味が悪く経口摂取が困難であった.
(比較例3) 実施例2において乳清蛋白質の代わりに大豆蛋白質を配合した以外は実施例2と同様の方法で大豆蛋白質栄養剤を調製した.得られた大豆蛋白質栄養剤は,チューブに詰まり継続投与不可能であった.また,風味が悪く経口摂取が困難であった.
Claims (9)
- 乳清蛋白質を有効成分として含有する褥瘡の治癒及び/または発生予防剤.
- 乳清蛋白質として一日あたり1.25〜2.0g/kg(体重)を経消化管的に投与されるものである請求項1に記載の褥瘡の治癒及び/または発生予防剤。
- 請求項1に記載の褥瘡の治癒及び/または発生予防剤を蛋白質成分として配合した乳清蛋白質配合栄養剤。
- 糖質,脂質,ビタミン,およびミネラルを配合した請求項2に記載の乳清蛋白質栄養剤.
- 前記ビタミンが,少なくともビタミンA及びビタミンCを含有する請求項4に記載の乳清蛋白質栄養剤.
- ミネラルが,少なくともカルシウム,鉄,亜鉛,及び銅を含有する請求項4または5に記載の乳清蛋白質栄養剤.
- 乳清蛋白質の含有量が,100kcalあたり2〜13.5gである請求項3〜6のいずれかに記載の乳清蛋白質栄養剤。
- 液状である請求項3〜7のいずれかに記載の乳清蛋白質栄養剤。
- 高圧蒸気滅菌されてなる請求項8に記載の乳清蛋白質栄養剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007255643A JP5221094B2 (ja) | 2007-09-28 | 2007-09-28 | 褥瘡患部の皮下筋層の再生剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007255643A JP5221094B2 (ja) | 2007-09-28 | 2007-09-28 | 褥瘡患部の皮下筋層の再生剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009084202A true JP2009084202A (ja) | 2009-04-23 |
JP5221094B2 JP5221094B2 (ja) | 2013-06-26 |
Family
ID=40658088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007255643A Active JP5221094B2 (ja) | 2007-09-28 | 2007-09-28 | 褥瘡患部の皮下筋層の再生剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5221094B2 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09327498A (ja) * | 1996-06-13 | 1997-12-22 | Terumo Corp | 医療用容器 |
JP2003137808A (ja) * | 2001-10-26 | 2003-05-14 | Kakunai Juyotai Kenkyusho:Kk | 新規経腸栄養剤の製造法 |
JP2007500208A (ja) * | 2003-05-22 | 2007-01-11 | エヌ.ブイ.・ヌートリシア | 慢性創傷の治療方法又は予防方法並びにそれに使用するためのグリシン及び/又はロイシンを含む完全栄養組成物 |
JP2009035491A (ja) * | 2007-07-31 | 2009-02-19 | Morinaga Milk Ind Co Ltd | 褥瘡改善剤 |
-
2007
- 2007-09-28 JP JP2007255643A patent/JP5221094B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09327498A (ja) * | 1996-06-13 | 1997-12-22 | Terumo Corp | 医療用容器 |
JP2003137808A (ja) * | 2001-10-26 | 2003-05-14 | Kakunai Juyotai Kenkyusho:Kk | 新規経腸栄養剤の製造法 |
JP2007500208A (ja) * | 2003-05-22 | 2007-01-11 | エヌ.ブイ.・ヌートリシア | 慢性創傷の治療方法又は予防方法並びにそれに使用するためのグリシン及び/又はロイシンを含む完全栄養組成物 |
JP2009035491A (ja) * | 2007-07-31 | 2009-02-19 | Morinaga Milk Ind Co Ltd | 褥瘡改善剤 |
Also Published As
Publication number | Publication date |
---|---|
JP5221094B2 (ja) | 2013-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2431142T3 (es) | Inhibidor de acumulación de grasa para el tratamiento de síndrome metabólico | |
EP2039365B1 (en) | Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level | |
Kassem | Future challenges of whey proteins | |
EP1040833A1 (en) | Bone resorption suppressing agent | |
US6649590B2 (en) | Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof | |
KR101433648B1 (ko) | 피부미용제 | |
JP2001346519A (ja) | 乳塩基性シスタチン高含有画分及びその分解物の製造方法 | |
JPWO2009057287A1 (ja) | 破骨細胞形成抑制用食品素材 | |
WO2018034345A1 (ja) | 抗がん剤に起因する末梢神経障害を改善するための組成物 | |
JP2002000193A (ja) | 乳塩基性シスタチン高含有画分及びその分解物の製造法 | |
JP5221094B2 (ja) | 褥瘡患部の皮下筋層の再生剤 | |
EP1602284A1 (en) | Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof | |
US11464835B2 (en) | Enzyme-treated milk product, preparation method thereof, composition, and products | |
KR101441728B1 (ko) | 골흡수 억제용 식품 소재 | |
TWI761523B (zh) | 營養組成物 | |
AU2017206200A1 (en) | Sensation-improving agent | |
JP7300243B2 (ja) | 栄養組成物 | |
US7998476B2 (en) | Method of treatment using Aspergillus oryzae protease | |
JP2017171595A (ja) | Bdnf産生促進剤 | |
CN105283197B (zh) | 痤疮的治疗和预防 | |
KR20210001780A (ko) | 나노콜라겐펩타이드 킬레이트 칼슘 및 그의 제조방법 | |
JPH08149954A (ja) | 新規蛋白質及び栄養組成物 | |
Sebestyen et al. | Pseudotumor cerebri in a toddler receiving recombinant human growth hormone | |
TW201511769A (zh) | 消炎劑 | |
WO2006059397A1 (ja) | 抗ストレス性食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120918 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121113 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20121113 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130305 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130307 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160315 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5221094 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |